| 1 |
Bracht H, Hafner S, Weiss M. Sepsis update: Definition and epidemiology[J]. Anasthesiol Intensivmed Notfallmed Schmerzther, 2019, 54(1): 10-20.
|
| 2 |
Jee Y, Carlson J, Rafai E, et al. Antimicrobial resistance: A threat to global health[J]. Lancet Infect Dis, 2018, 18(9): 939-940.
|
| 3 |
Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited[J]. BMC Med, 2017, 15(1): 15.
|
| 4 |
Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients′exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial[J]. Lancet, 2010, 375(9713): 463-474.
|
| 5 |
Song X, Song Y, Zhang X, et al. Soluble triggering receptor expressed on myeloid cells-1 as a novel marker for abdominal sepsis[J]. Surg Infect (Larchmt), 2017, 18(5): 577-581.
|
| 6 |
Hamed S, Behnes M, Pauly D, et al. Diagnostic value of Pentraxin-3 in patients with sepsis and septic shock in accordance with latest sepsis-3 definitions[J]. BMC Infect Dis, 2017, 17(1): 554.
|
| 7 |
Yoon SH, Kim EH, Kim HY, et al. Presepsin as a diagnostic marker of sepsis in children and adolescents: a systemic review and meta-analysis[J]. BMC Infect Dis, 2019, 19(1): 760.
|
| 8 |
Tan M, Lu Y, Jiang H, et al. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: A systematic review and meta-analysis[J]. J Cell Biochem, 2019, 120(4): 5852-5859.
|
| 9 |
Gbinigie OA, Onakpoya IJ, Richards GC, et al. Biomarkers for diagnosing serious bacterial infections in older outpatients: a systematic review[J]. BMC Geriatr, 2019, 19(1): 190.
|
| 10 |
Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use[J]. Clin Chem Lab Med, 2019, 57(9): 1308-1318.
|
| 11 |
Tang JH, Gao DP, Zou PF, et al. Comparison of serum PCT and CRP levels in patients infected by different pathogenic microorganisms: a systematic review and meta-analysis[J]. Braz J Med Biol Res, 2018, 51(7): e6783.
|
| 12 |
Wiwatcharagoses K, Kingnakom A. Procalcitonin under investigation as a means of detecting severe sepsis, septic shock and bacteremia at emergency department, rajavithi hospital[J]. J Med Assoc Thai, 2016, 99(Suppl 2): S63-S68.
|
| 13 |
Mathew B, Roy DD, Kumar TV. The use of procalcitonin as a marker of sepsis in children[J]. J Clin Diagn Res, 2013, 7(2): 305-307.
|
| 14 |
Nargis W, Ibrahim MD, Ahamed BU. Procalcitonin versus C-reactive protein: usefulness as biomarker of sepsis in ICU patient[J]. Int J Crit Illn Inj Sci, 2014, 4: 195-199.
|
| 15 |
Yang AP, Liu J, Yue LH, et al. Neutrophil CD64 combined with PCT, CRP and WBC improves the sensitivity for the early diagnosis of neonatal sepsis[J]. Clin Chem Lab Med, 2016, 54(2): 345-351.
|
| 16 |
Barrier KM. Summary of the 2016 international surviving sepsis campaign：a clinician′s guide[J]. Crit Care Nurs Clin North Am, 2018, 30(3): 311-321.
|
| 17 |
Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients′exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial[J]. Lancet, 2010, 375(9713): 463-474.
|
| 18 |
de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial[J]. Lancet Infect Dis, 2016, 16(7): 819-827.
|
| 19 |
Wirz Y, Branche A, Wolff M, et al. Management of respiratory infections with use of procalcitonin: Moving toward more personalized antibiotic treatment decisions[J]. ACS Infect Dis, 2017, 3(12): 875-879.
|
| 20 |
Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-guided antibiotic discontinuation and mortality in critically Ill adults: A Systematic Review and Meta-analysis[J]. Chest, 2019, 155(6): 1109-1118.
|
| 21 |
降钙素原急诊临床应用专家共识组. 降钙素原(PCT)急诊临床应用的专家共识[J]. 中华急诊医学杂志，2012, 21(9): 944-951.
|
| 22 |
Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial[J]. Crit Care Med, 2011, 39(9): 2048-2058.
|
| 23 |
Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America[J]. Clin Infect Dis, 2016, 62: e51-e77.
|
| 24 |
Braha B, Mahmutaj D, Maxhuni M. Correlation of procalcitonin and C-reactive protein with intra-abdominal hypertension in intra-abdominal infections: their predictive role in the progress of the disease[J]. Open Access Maced J Med Sci, 2018, 6(3): ？479-484.
|
| 25 |
Zhou G, Ho KM. Procalcitonin concentrations as a predictor of unexpected readmission and mortality after intensive care unit discharge: A retrospective cohort study[J]. J Crit Care, 2016, 33: 240-244.
|
| 26 |
Sager R, Kutz A, Mueller B, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited[J]. BMC Med, 2017, 15(1): 15.
|
| 27 |
Yavuzer H, Cengiz M, Yavuzer S, et al. Procalcitonin and pentraxin-3：current biomarkers in inflammation in white coat hypertension[J]. J Hum Hypertens, 2016, 30(7): 424-429.
|
| 28 |
Hernán T, Mariana D, Alexis M, et al. Pro-calcitonin and inflammation in chronic hemodialysis[J]. Medicina (B Aires), 2013, 73(5): 411-416.
|
| 29 |
Bajpai D, Pednekar S, Pandey D, et al. Association of plasma procalcitonin with various components of metabolic syndrome and insulin resistance in Urban Indian Population: A novel biomarker[J]. J Assoc Physicians India, 2018, 66(12): 35-38.
|
| 30 |
Wang WJ, Zhang XM, Ge N, et al. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4，698 cases[J]. Crit Care, 2014, 18(1): R4.
|
| 31 |
Ko YH, Ji YS, Park SY, et al. Procalcitonin determined at emergency department as na early indicator of progression to septic shock in patient with sepsis associated with ureteral calculi[J]. Int Braz J Urol, 2016, 42(2): 270-276.
|
| 32 |
Wang X, Sun Y, Shao X. Predictive value of procalcitonin for infection of patients with type-2 diabetes mellitus[J]. Exp Ther Med, 2019, 18(1): 722-728.
|
| 33 |
胡雍军，张俊鸿，熊 玮. 脓毒症患者血清降钙素原水平的影响因素分析[J]. 第三军医大学学报，2020, 42(22): 2219-2223.
|
| 34 |
胡雍军，郜 攀，章陈晨. 血清降钙素原联合呼吸频率检查对脓毒性休克预测的研究[J]. 重庆医学，2021, 50(21): 3639-3642, 3646.
|
| 35 |
De Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050？[J]. PLOS Med, 2016, 13(11): e1002184.
|
| 36 |
De Waele JJ, Boelens J, Leroux-Roels I. Multidrug-resistant bacteria in ICU: fact or myth[J]. Curr Opin Anaesthesiol, 2020, 33(2): 156-161.
|
| 37 |
Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units[J]. JAMA, 2009, 302(21): 2323-2329.
|
| 38 |
Klein KP, Cremer OL, van Vught LA, et al. Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: a cohort study[J]. Crit Care, 2015, 19(1): 319.
|
| 39 |
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47(11): 1181-1247.
|
| 40 |
Reinhart K, Meisner M. Biomarkers in the critically ill patient: procalcitonin[J]. Crit Care Clin, 2011, 27(2): 253-263.
|
| 41 |
Schwarz S, Bertram M, Schwab S. Serum procalcitonin levels in bacterial and abacterial meningitis[J]. Crit Care Med, 2000, 28(6): 1828-1832.
|
| 42 |
Pfister R, Kochanek M, Leygeber T, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis[J]. Crit Care, 2014, 18(2): R44.
|
| 43 |
Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections[J]. Cochrane Database Syst Rev, 2017, 10(10): D7498.
|
| 44 |
Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients′exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial[J]. Lancet, 2010, 375(9713): 463-474.
|
| 45 |
Papp M, Kiss N, Baka M, et al. Procalcitonin-guided antibiotic therapy may shorten length of treatment and may improve survival-a systematic review and meta-analysis[J]. Crit Care, 2023, 27(1): 394.
|
| 46 |
Paudel R, Dogra P, Montgomery-Yates AA, et al. Procalcitonin: A promising tool or just another overhyped test? [J]. Int J Med Sci, 2020, 17(3): 332-337.
|
| 47 |
Mierzchala-Pasierb M, Lipinska-Gediga M. Sepsis diagnosis and monitoring-procalcitonin as standard, but what next？[J]. Anaesthesiol Intensive Ther, 2019, 51(4): 299-305.
|
| 48 |
马 兰，胡迎春，张 川，等. 脓毒症关键基因的筛选与生物信息学分析[J]. 西南医科大学学报，2022, 45(3): 206-210.
|